AstraZeneca(US:AZN) Mei Ri Jing Ji Xin Wen·2025-04-30 09:23Core Insights - AstraZeneca reported Q1 2025 revenue of $13.588 billion, a 10% year-over-year increase, driven by double-digit growth in oncology and biopharmaceuticals [1] - The company reaffirmed its full-year guidance, expecting high single-digit revenue growth and low double-digit core earnings per share growth for 2025 [1] Revenue Breakdown - In Q1 2025, AstraZeneca's revenue from the US market was $5.646 billion, a 10% increase, while revenue from China was $1.805 billion, a 5% increase, accounting for 13% of the company's global market share [1] - The oncology segment generated $5.643 billion, a 13% increase, representing 42% of total revenue, remaining the primary revenue source [2] Legal Matters - AstraZeneca is under investigation for allegedly evading import taxes exceeding $1.6 million related to the drug Enhertu, with potential fines ranging from $1 million to $8 million if found liable [1] - The company received a notice regarding alleged violations of personal information rights, asserting no illegal gains from such actions and pledging cooperation with Chinese authorities [2] Product Performance - Enhertu's global sales rose from $879 million in the previous year to $1.086 billion in Q1 2025, with a significant contribution from the Chinese market, where sales increased by 57.1% [3] - Following its inclusion in China's National Reimbursement Drug List, Enhertu has seen rapid growth in indications for HER2-positive and HER2-low expressing breast cancer [3]